Patrick Hwu

Patrick Hwu's AcademicInfluence.com Rankings

Patrick Hwu

Philosophy

#5438

World Rank

#8237

Historical Rank

Logic

#2722

World Rank

#3753

Historical Rank

philosophy Degrees

Patrick Hwu

Biology

#7268

World Rank

#10163

Historical Rank

Immunology

#388

World Rank

#403

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Patrick Hwu Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Patrick Hwu's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. (2012) (6726)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002) (2901)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (2003) (2799)
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients (2018) (2594)
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1998) (1897)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003) (1591)
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities (2018) (1415)
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (2006) (1088)
B cells and tertiary lymphoid structures promote immunotherapy response (2020) (1046)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. (2016) (1018)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy (2016) (860)
PD-L1 Expression in Triple-Negative Breast Cancer (2014) (833)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma (2013) (796)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. (2003) (784)
Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation (2000) (747)
T helper 17 cells promote cytotoxic T cell activation in tumor immunity. (2009) (726)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. (2016) (685)
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (2011) (645)
NRAS mutation status is an independent prognostic factor in metastatic melanoma (2012) (605)
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (2017) (555)
Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma (2018) (500)
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. (1999) (446)
Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-61 (2004) (437)
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
Prognostic factors for survival in melanoma patients with brain metastases (2011) (430)
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. (1999) (421)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion (2013) (401)
Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma (2001) (379)
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma (2002) (368)
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients (2012) (352)
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity (2015) (339)
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. (2018) (337)
Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases (1997) (336)
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. (1998) (334)
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals (2001) (326)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice (2012) (320)
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. (2012) (313)
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma (2016) (310)
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. (2008) (306)
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. (1999) (284)
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. (1995) (278)
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. (2002) (262)
Targeting the indoleamine 2,3-dioxygenase pathway in cancer (2015) (261)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma (2012) (256)
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain (1993) (247)
In vivo antitumor activity of interleukin 21 mediated by natural killer cells. (2003) (246)
Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. (1996) (239)
Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. (2011) (215)
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function (2017) (207)
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer (2008) (201)
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. (2018) (193)
Pathways and therapeutic targets in melanoma (2014) (187)
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. (2012) (187)
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. (2014) (185)
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). (2013) (185)
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. (2003) (182)
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) (181)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates (2009) (178)
Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses (2010) (177)
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (2019) (168)
Peli1 negatively regulates T-cell activation and prevents autoimmunity (2011) (163)
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. (2019) (161)
Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations (1999) (160)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. (2017) (160)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses (2007) (136)
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series (2017) (135)
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. (2018) (132)
Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations (2014) (130)
Harnessing the power of the immune system to target cancer. (2013) (130)
Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo (2004) (130)
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. (2000) (128)
Hypo Adenosine-to-Inosine miR-455-5p Editing Promotes Melanoma Growth and Metastasis (2015) (127)
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade (2020) (127)
Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy (2013) (123)
Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma (2011) (123)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). (2020) (122)
Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. (1993) (121)
Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation (2014) (121)
Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function (2011) (121)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. (2017) (119)
Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma (2014) (118)
Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens (2003) (118)
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma (2016) (116)
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. (2003) (114)
Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma (2012) (114)
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms (2006) (114)
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib (2008) (114)
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma (2015) (114)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (2018) (113)
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. (2010) (112)
Dual-specific T cells combine proliferation and antitumor activity (2002) (112)
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. (2009) (111)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (110)
IFN-α Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity1 (2009) (109)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. (2019) (108)
Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression (2012) (108)
BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency (2012) (107)
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set (2016) (105)
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma (2017) (105)
Immuno-genomic landscape of osteosarcoma (2020) (103)
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (2018) (100)
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. (2003) (99)
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor. (1993) (99)
MART-1–Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro (2009) (97)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy (2020) (97)
Gene therapy: progress and prospects. (1994) (95)
RNA editing derived epitopes function as cancer antigens to elicit immune responses (2018) (92)
Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma (2013) (91)
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. (2020) (90)
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. (1996) (89)
Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen‐specific T lymphocytes (2000) (89)
White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy (2011) (88)
Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma (2008) (87)
Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. (2000) (87)
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. (2002) (87)
PD-L 1 Expression in Triple-Negative Breast Cancer (2014) (83)
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. (2007) (83)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes (2017) (82)
Combined-modality therapy for patients with regional nodal metastases from melanoma. (2006) (82)
Immunization against endogenous retroviral tumor-associated antigens. (2001) (79)
Biochemotherapy in patients with advanced head and neck mucosal melanoma (2008) (79)
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. (1995) (78)
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome (2018) (77)
Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. (1996) (77)
Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy. (2009) (75)
Mobilization of Dendritic Cell Precursors in Patients With Cancer by Flt3 Ligand Allows the Generation of Higher Yields of Cultured Dendritic Cells (2002) (72)
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. (2014) (72)
CD40-Mediated Induction of CD4 and CXCR4 on B Lymphocytes Correlates with Restricted Susceptibility to Human Immunodeficiency Virus Type 1 Infection: Potential Role of B Lymphocytes as a Viral Reservoir (1999) (71)
A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma (2009) (70)
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. (1996) (70)
The Development of Gene Therapy for the Treatment of Cancer (1993) (68)
Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma (2003) (67)
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. (2015) (66)
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy (2007) (66)
Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma (2017) (66)
Phase 2 open-label study of weekly docosahexaenoic acid–paclitaxel in patients with metastatic uveal melanoma (2010) (64)
A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen (1998) (63)
A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. (2009) (63)
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. (2000) (62)
A phase III multi-institutional randomized study of immunization with the gp100: 209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. (2009) (61)
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain (2017) (61)
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
Antitumor Activity Mediated by CpG: The Route of Administration is Critical (2011) (60)
Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma (2011) (59)
Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100 (2001) (59)
Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen–Specific, Skin-Homing T Lymphocytes (2006) (58)
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. (2012) (57)
In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). (1999) (57)
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression (2018) (56)
A Critical Assessment of Adjuvant Radiotherapy for Inguinal Lymph Node Metastases from Melanoma (2004) (55)
Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report (2016) (55)
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 (2019) (54)
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma (2016) (53)
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma (2012) (53)
Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver: Response, Survival, and Prognostic Factors (2010) (53)
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes (2017) (52)
T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors (2018) (52)
Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. (2013) (52)
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. (2015) (52)
Recognition of human colon cancer by T cells transduced with a chimeric receptor gene (2000) (52)
Treating cancer by targeting the immune system. (2010) (51)
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. (2007) (51)
Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. (1992) (51)
Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma (2012) (51)
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases (2012) (51)
Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. (1992) (50)
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy (2017) (50)
Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators (2017) (50)
Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. (2017) (50)
Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma (2014) (49)
Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy (2011) (49)
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy (2019) (48)
Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma (2015) (48)
Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy (2014) (47)
Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy (2017) (47)
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity. (2017) (46)
The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. (1994) (46)
Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis (2007) (46)
GPNMB expression in uveal melanoma: a potential for targeted therapy (2009) (45)
Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin (2018) (45)
Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma (2016) (44)
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade (2017) (44)
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2 (2018) (43)
Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention (2006) (43)
BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties (2015) (43)
Assessment of needs, health-related quality of life, and satisfaction with care in breast cancer patients to better target supportive care (2013) (42)
Advances in the development of cancer immunotherapies. (2013) (42)
Strategies for improving the management of immune-related adverse events (2020) (42)
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 (2016) (41)
The immunotherapy of patients with ovarian cancer. (2002) (40)
Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2). (1993) (39)
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. (2016) (39)
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer (2017) (38)
Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients With Impaired Liver Function (2011) (38)
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study (2017) (38)
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. (2022) (37)
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model (2018) (37)
Advances in the treatment of metastatic melanoma: adoptive T-cell therapy. (2012) (37)
Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter (2017) (37)
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon‐V600 mutations in cutaneous melanoma patients (2017) (35)
Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo (2012) (34)
A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence (2009) (34)
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer (2013) (34)
Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. (2000) (33)
Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma (2016) (33)
IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation (2016) (33)
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine (2019) (32)
Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. (2020) (32)
AACR Cancer Progress Report 2016 (2016) (32)
Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. (2017) (31)
Microenvironment and Immunology PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-g Inducible Chemokines (2012) (31)
Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. (2010) (31)
A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes (2017) (31)
Presentation of Tumor Antigens by Dendritic Cells Genetically Modified With Viral and Nonviral Vectors (2006) (30)
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance (2015) (30)
A phase II study of gefitinib in patients with metastatic melanoma (2011) (30)
Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy (2021) (29)
A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). (2020) (29)
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations (2018) (29)
CD 40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigen-presenting Cells That Can Generate Specific T Cells 1 (2003) (29)
Circulating Tumor Cells and Early Relapse in Node-positive Melanoma (2020) (29)
IL-21 Is an Antitolerogenic Cytokine of the Late-Phase Alloimmune Response (2011) (28)
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma (2019) (28)
MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells (2002) (27)
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. (2002) (27)
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute (2016) (27)
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma (2012) (26)
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma (2017) (26)
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report (2015) (26)
PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. (2012) (26)
Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. (2009) (26)
SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity (2017) (25)
Overexpression of Interleukin 21 Induces Expansion of Hematopoietic Progenitor Cells (2006) (25)
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. (1992) (25)
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients (2009) (25)
Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy (2012) (25)
Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2 (2012) (24)
Antitumor activity of dual-specific T cells and influenza virus (2007) (24)
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma (2011) (24)
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma (2018) (24)
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM). (2019) (23)
Adjuvant Ipilimumab in High-Risk Uveal Melanoma (2019) (23)
The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program (2011) (22)
Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype (2012) (22)
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy (2020) (22)
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. (2008) (22)
Systemic Therapy for Unresectable Metastatic Melanoma: Impact of Biochemotherapy on Long-Term Survival (2008) (22)
New insights on the role of CD8+CD57+ T-cells in cancer (2012) (21)
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. (2021) (21)
Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development (2014) (21)
403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer (2020) (20)
T-cell lymphoma secondary to checkpoint inhibitor therapy (2020) (20)
Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. (2011) (19)
Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases (2017) (19)
A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy (2012) (19)
Differential Expression of the G-Protein–Coupled Formyl Peptide Receptor in Melanoma Associates With Aggressive Phenotype (2013) (19)
Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference (2006) (19)
Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma (2009) (19)
Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination (2016) (19)
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. (2020) (19)
Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM). (2018) (19)
Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells (2016) (19)
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. (2017) (19)
Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. (2016) (18)
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). (2017) (18)
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. (2022) (18)
Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study (2019) (18)
Bone morphogenetic protein 7 promotes resistance to immunotherapy (2020) (18)
The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity (2015) (18)
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. (2016) (17)
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer (2020) (17)
MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma (2019) (17)
General Discussion 3 (1994) (17)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Letter (2013) (17)
The Use of Gene‐Modified Tumor‐Infiltrating Lymphocytes for Cancer Therapy (1994) (16)
Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. (2021) (16)
Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer (2018) (16)
Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. (2012) (16)
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma (2016) (16)
Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma (2011) (16)
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. (2018) (15)
Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. (2018) (15)
Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines. (2011) (15)
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy (2019) (15)
Precision medicine: Clinical outcomes including long-term survival according to the pathway targeted and treatment period–The IMPACT study. (2018) (15)
Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. (2018) (15)
Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. (2017) (15)
Current challenges in cancer gene therapy (1997) (15)
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. (2013) (14)
Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity (2021) (14)
A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma (2008) (14)
Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature (2019) (14)
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators (2021) (14)
Molecular basis of antibody binding to mucin glycopeptides in lung cancer (2015) (13)
Summary of the primer on tumor immunology and the biological therapy of cancer (2009) (13)
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy (2022) (13)
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma (2020) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM) (2007) (13)
A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma (2008) (13)
Novel Treatments in Development for Melanoma. (2016) (13)
Melanoma and other skin tumors (2012) (13)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti–PD‐1 in patients with metastatic melanoma (2019) (12)
Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. (1994) (12)
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida (2022) (12)
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (2020) (12)
Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma (2017) (12)
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-&agr; in patients with metastatic melanoma (2014) (12)
Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. (2015) (12)
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations (2021) (12)
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma (2021) (11)
Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis (2007) (11)
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? (2011) (11)
Ipilimumab plus temozolomide in metastatic melanoma. (2011) (11)
A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas. (2020) (11)
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (11)
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy (2022) (11)
Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. (2011) (11)
Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs (2002) (11)
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers (2020) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
TGF-β1 Induces Preferential Rapid Expansion and Persistence of Tumor Antigen-specific CD8+ T Cells for Adoptive Immunotherapy (2010) (11)
Phase II Study of TRIplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases. (2021) (10)
A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. (2017) (10)
Lovastatin Inhibits T-cell Proliferation While Preserving the Cytolytic Function of EBV, CMV, and MART-1-specific CTLs (2010) (10)
CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner (2017) (10)
Strong emerging rationale for combining oncogene-targeted agents with immunotherapy (2013) (10)
1187PA Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma (2017) (10)
A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403–455) (2011) (10)
Evaluation of tolerability, safety, and pharmacokinetics of INO-1001 plus temozolomide (TMZ) in patients with unresectable stage III/IV melanoma. (2006) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. (2021) (10)
Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity. (2016) (10)
Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers (2021) (10)
Study on Adoptive Immunotherapy Using Gene-Modified TCells for Ovarian Cancer (2006) (9)
A toll-like receptor agonist to drive melanoma regression as a vaccination adjuvant or by direct tumor application. (2017) (9)
Expression and clinical correlations of PRAME in sarcoma subtypes. (2016) (9)
A phase II study of gefitinib in patients with metastatic melanoma. (2009) (9)
Forging a link between oncogenic signaling and immunosuppression in melanoma (2013) (9)
Immunotherapy of melanoma: an update. (2011) (9)
Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2 (2016) (9)
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity (2020) (9)
Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy (2010) (9)
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma (2010) (9)
Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss. (2018) (8)
Recent developments in the implementation of novel designs for early-phase combination studies. (2015) (8)
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy (2022) (8)
Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. (2003) (8)
Challenges of Chemosensitivity Testing (2006) (8)
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth12 (2017) (8)
Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy (2016) (8)
Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma. (2016) (8)
Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. (2019) (8)
Costimulation through 4-1BB/CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy (66.21) (2011) (8)
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. (2022) (8)
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state (2021) (7)
Designed improvement to T-cell immunotherapy by multidimensional single cell profiling (2021) (7)
Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. (2021) (7)
GNA11 Mutation in a Patient With Cutaneous Origin Melanoma (2016) (7)
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma (2021) (7)
Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1. (2016) (7)
Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis. (2017) (7)
Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma. (2018) (7)
CD40 ligand and lipopolysaccharide enhance the in vitro generation of melanoma-reactive T-cells. (2002) (7)
Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. (2018) (7)
An antibody‐drug conjugate targeting a GSTA glycosite‐signature epitope of MUC1 expressed by non‐small cell lung cancer (2020) (7)
Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 (2017) (7)
CXCL9, CXCL10 and IFNγ favor the accumulation of infused T cells in tumors following IL-12 plus doxorubicin treatment (2016) (6)
A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM). (2017) (6)
Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes. (2020) (6)
IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma (2021) (6)
Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes. (1992) (6)
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment (2008) (6)
Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination (2013) (6)
The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM). (2017) (6)
Inhibiting Type I arginine methyltransferase activity promotes the T cell mediated antitumor immune response. (2022) (6)
2E8 Binds to the High Affinity I-domain in a Metal Ion-dependent Manner (2010) (6)
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma (2015) (6)
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma (2009) (6)
Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver (2018) (5)
Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss. (2020) (5)
Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck (2011) (5)
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade (2022) (5)
Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome (2017) (5)
Preliminary results from a phase I/II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy (2007) (5)
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (5)
Intratumoral (i.t.) IMO-2125 (IMO), a TLR9 agonist, in combination with ipilimumab (ipi) in PD-(L)1 refractory melanoma (RM). (2017) (5)
Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy (2012) (4)
Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2. (2011) (4)
Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application (2018) (4)
Clinical characteristics of patients with non-V600 BRAF mutant melanomas. (2014) (4)
Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM) (2015) (4)
Outcomes of metastatic melanoma (MM) patients (pts) after discontinuation of anti-Programmed-Death 1 (PD1) therapy without disease progression. (2018) (4)
1212TiPPIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies (2017) (4)
Recent Advancements in Pancreatic Cancer Immunotherapy (2016) (4)
Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P). (2009) (4)
Spotlight on Clinical Response Activity of dasatinib against L 576 P KIT mutant melanoma : Molecular , cellular , and clinical correlates (2009) (4)
Temporally-Dependent Intracranial Control of Melanoma Brain Metastasis by Stereotactic Radiation Therapy in Patients Treated With Immune Checkpoint Blockade (2015) (4)
Development of brain metastases in patients with metastatic melanoma treated with ipilimumab plus temozolomide. (2012) (4)
The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2. (2010) (4)
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. (2021) (4)
A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma (2007) (4)
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma (2021) (4)
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary (2022) (4)
Melanoma and immunotherapy bridge (2016) (4)
Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy (2014) (4)
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC. (2018) (4)
P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies (2017) (4)
IMCT-07THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD). (2015) (4)
Adoptive Cell Therapy for the Treatment of Metastatic Melanoma (2012) (4)
Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells (2013) (4)
Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. (2019) (3)
Bone marrow derived macrophages have polyamine and ectoenzyme phenotypes distinct from resident macrophages. (1988) (3)
A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). (2018) (3)
A phase Ib study of endogenous SLC45A2-specific cytotoxic T cells for the treatment of patients with metastatic uveal melanoma. (2020) (3)
A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). (2016) (3)
CHARACTERIZATION OF HUMAN TUMOR CELL LINES TRANSDUCED WITH cDNA CODING EITHER TUMOR NECROSIS FACTOR (TNF) OR INTERLEUKIN-2 (IL-2) (1992) (3)
A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. (2020) (3)
Clinical characteristics of melanoma patients with non-V600E/K BRAF mutations. (2013) (3)
Phase II study of 'hybrid' biochemotherapy for advanced melanoma. (2006) (3)
Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). (2017) (3)
293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101) (2020) (3)
T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand (2012) (3)
Abstract 5652: Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma (2017) (3)
Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy. (2009) (3)
Multi-modal molecular programs regulate melanoma cell state (2022) (3)
Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma. (2006) (3)
Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. (2017) (3)
Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study. (2016) (3)
Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma. (2017) (3)
Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. (2016) (3)
Erratum: Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis (Gene Therapy (2007) vol. 14 (316-323) 10.1038/sj.3302864) (2007) (3)
Lymphocyte-specific protein tyrosine kinase expression predicts survival in ovarian high-grade serous carcinoma (2019) (2)
HLA-A0201 positive pancreatic cell lines: new findings and discrepancies (2007) (2)
Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma (2003) (2)
Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. (2014) (2)
Prognostic factors for overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with immune checkpoint inhibitors: A single institution study of 696 pts. (2017) (2)
Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. (2014) (2)
NMDA Receptor-PSD-95 Protein Interactions Treatment of Ischemic Brain Damage by Perturbing (2006) (2)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (2)
Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma. (2010) (2)
Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (2019) (2)
Intratumoral positron emission cancer therapy (IPECT) using F-18 FDG, Cu-64 Cl and Ga-68 Cl (2013) (2)
The neoantigen landscape and immune regulators in cervical cancer. (2017) (2)
Rethinking the immunotherapy numbers game (2022) (2)
Targeted next generation sequencing of sarcomas for identification of therapeutic targets. (2013) (2)
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
Presence of survivin-specific cytotoxic T-lymphocytes (CTLs) in pancreatic cancer patients, and specific killing of human pancreatic carcinoma cells in vitro by survivin-specific CTLs (2007) (2)
Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM). (2013) (2)
Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma. (2016) (2)
Abstract 1580: LL-37-mediates tumor antigen-specific-T cell expansion and tumor regression (2012) (2)
Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome (2019) (2)
Prognostic factors determining long term survival of patients with unresectable stage III and stage IV metostatic melanoma (MM) treated with combination therapy or IL-2 based biochemotherapy (BCC) (2005) (2)
Phase I trial of temozolomide, thalidimide, and lomustine in patients with metastatic melanoma in the brain. (2011) (2)
Correlation of immune response with clinical outcomes in melanoma patients receiving adjuvant therapy of pegylated interferon alpha-2b combined with gp100 peptide vaccine. (2014) (2)
Whole-brain radiation therapy in melanoma: an open question – Authors' reply (2010) (2)
Clinical study of personalized neoantigen peptide vaccination in advanced NSCLC patients (2019) (2)
Targeting Genetic Aberrations in Uveal Melanoma (2010) (2)
BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma. (2016) (2)
Phase II open-label study of weekly taxoprexin (TXP) as first-line treatment in patients with metastatic cutaneous and mucosal malignant melanoma (2008) (1)
Immunization against Endogenous Retroviral Tumor-associated Antigens 1 (2001) (1)
Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation (2014) (1)
MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer (2019) (1)
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males (2022) (1)
Outcomes of patients with melanoma brain metastases (MBM) treated with standard of care therapy after being excluded from MBM-specific clinical trials (2019) (1)
Does complete response (CR) with systemic therapy (SRx) translate into long term survival in stage IV melanoma (MM) (2008) (1)
Clinical Success of Adoptive Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes (2015) (1)
Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients. (2010) (1)
CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla (2015) (1)
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling (2022) (1)
Oncology and public health (2012) (1)
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response. (2015) (1)
Abstract CT052: A phase I dose escalation trial of vemurafenib in combination with the mTOR inhibitor everolimus for melanoma and non-melanoma cancers with a BRAF aberration (2016) (1)
BTLA: new biomarker for a highly proliferative CD8+ TIL subset associated with melanoma regression during adoptive cell therapy (P2189) (2013) (1)
Abstract 2562: Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4 (2018) (1)
Abstract B105: HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes (2016) (1)
A single-institution experience with the pembrolizumab (PEM) Expanded Access Program (EAP). (2015) (1)
Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts). (2017) (1)
311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma (2020) (1)
Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance (2022) (1)
Normal development and fertility of Fut1, Fut2, and Sec1 triple knockout mice (2019) (1)
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: A single institution experience (2008) (1)
FRI0604 Successful treatment of arthritis induced by checkpoint inhibitors with anti–interleukin-6 receptor antibody: a case series (2017) (1)
Biology of Human Tumors Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB / C Melanoma Patients with BRAF V 600 Mutations (2014) (1)
The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. (2016) (1)
Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development (2014) (1)
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma. (2018) (1)
A pharmacokinetic comparison of the Marqibo 3 and 5 vial injection kits in metatastic melanoma patients (2007) (1)
Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer. (2018) (1)
Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy. (2018) (1)
Development of a Novel Anti-SSTR Bispecific T-Cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors (2023) (1)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (1)
Abstract 5648: Combined immune checkpoint targeting with anti-PD-1 plus anti-CD40 antibodies as the most effective approach to eradicate head and neck squamous cell carcinomas (HNSCCs) in mouse models (2017) (1)
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma (2017) (1)
Abstract 4938: OX40 agonist antibody-based combination therapy with PI3Kβ selective inhibitor enhances T cell immunity (2018) (1)
BRAF and NRAS mutations in Metastatic Melanoma Patients with Leptomeningeal Disease. (2015) (1)
BRAF, NRAS, and KIT mutational analysis of spindle cell melanoma. (2011) (1)
Obesity is associated with altered tumor metabolism in metastatic melanoma. (2022) (1)
A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma. (2015) (1)
Detection and Characterization of a Novel Subset of CD 8 + CD 57 + T-cells in 1 Metastatic Melanoma with an Incompletely-Differentiated Phenotype 2 (2012) (1)
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers. (2018) (1)
Randomized trial of two schedules of palonosetron for the prevention of nausea and vomiting in patients with metastatic melanoma receiving interleukin-2-based concurrent biochemotherapy. (2009) (1)
Abstract CT156: Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response (2017) (1)
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma (2020) (1)
Immunotherapy comes of age: overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer (2007) (1)
Lymphodepletion (LD), tumor-infiltrating lymphocytes (TIL) and high (HD-IL2) versus low-dose (LD-IL2) IL-2 followed by pembrolizumab (pembro) in patients (pts) with metastatic melanoma (MM). (2019) (1)
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. (2022) (1)
The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center. (2017) (1)
High-throughput screening of myxoid liposarcoma cell lines reveals survivin as a potential novel druggable target (2017) (1)
Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (NCT03026062) (2021) (1)
Abstract #LB-148: Mast cells in the tumor microenvironment are essential for the tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) (2009) (0)
Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemonaïve patients with metastatic melanoma (MM). (2015) (0)
Abstract 3640: Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM) (2018) (0)
TITLE : BAP 1 loss of function promotes liver tropism of uveal melanoma cells in vivo (2016) (0)
Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy (2013) (0)
and remain responsive to antigen Interleukin-2-transduced lymphocytes grow in an autocrine fashion (2011) (0)
Abstract PO015: The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer (2021) (0)
Charge-based interactions through peptide position 4 drive diversity of antigen presentation by human leukocyte antigen class I molecules (2022) (0)
The metabolic basis of resistance to Adoptive T Cell Therapy (ACT) in patients with solid tumors (2018) (0)
Multi-spatial whole-lesion molecular heterogeneity of an immunotherapy-resistant metastatic melanoma. (2018) (0)
Abstract B022: Intratumoral CD40 activation and checkpoint blockade induces systemic anti-melanoma immunity that eradicates disseminated tumors (2016) (0)
Prognostic and biologic significance of high LCK expression in ovarian cancer (2015) (0)
What the future holds for gene therapy (1994) (0)
187 Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival (2021) (0)
Integrated profiling of T cells and tumor cells demonstrates metabolic adaptation essential for melanoma cell therapy (2019) (0)
The tumor immune microenvironment shapes response to pembrolizumab in microsatellite instability-high endometrial cancer (2021) (0)
Predictive Biomarkers and Personalized Medicine Speci fi c Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-In fi ltrating Lymphocytes in Metastatic Melanoma Patients (2012) (0)
54 Prognostic value of T cell immunoscore estimated from transcriptomic data in patients with advanced malignancies treated with immune checkpoint inhibitors (2022) (0)
822 Favorable response of melanoma to TIL therapy associated with IFN-g regulated inflammatory pathway (2019) (0)
Celebrating a decade of the Journal for ImmunoTherapy of Cancer (2022) (0)
Abstract B110: Topoisomerase I inhibitors enhance efficacy of immunotherapy through a p53 regulatory pathway (2016) (0)
Lymphocytes a double specificite actives et procedes d'utilisation de ceux-ci (2002) (0)
You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes (2015) (0)
Abstract B118: Using a high throughput T-cell cytotoxicity assay to develop combination strategies for immunotherapy (2016) (0)
517 Long-term efficacy of intrathecal interleukin-2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD) (2015) (0)
Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males (2022) (0)
Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. (2017) (0)
Abstract A09: Characteristics of uveal melanoma patients with central nervous system metastases (2020) (0)
Abstract 1599: SMARCA4 regulates tumor resistance to anti-tumor immune response (2021) (0)
Abstract 3822: Immunosuppressive role of mast cells is essential for the tumorigenesis of pancreatic ductal adenocarcinoma (PDAC) (2010) (0)
Following Antigenic Restimulation In Vitro Capability Improved Survival and Expansion Maintaining CD28 Expression Have Tumor-Infiltrating Lymphocytes Specific Melanoma - MART-1 (2009) (0)
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
Abstract B152: Increasing the antitumor efficacy of immunotherapy in melanoma by using topoisomerase I inhibitors (2016) (0)
Identification of prognostic factors predictive of CNS metastasis in patients (pts) with advanced unresectable metastatic melanoma (MM). (2006) (0)
Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy (2013) (0)
Monoclonal Antibodies Progress To the Next Generation (1995) (0)
Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy (2020) (0)
A Novel Strategy for Generation of Human Tumor-Specific T Cell Clones for Adoptive Transfer. (2006) (0)
Abstract 532: Circulating myeloid precursor profile as potential marker to differentiate radiation changes from tumor recurrence after brain stereotactic radiosurgery (2015) (0)
Digital Multiplexed Quantification of Both T-Cell Receptor β-Chain and α-Chain Diversity in T Cells Using the Nanostring nCounter Assay System (2011) (0)
Radiation Followed By an Anti-OX40 Immune Therapy Inhibits Anti-PD1-Resistant Tumors and Promotes Abscopal Effects (2017) (0)
Imaging , Diagnosis , Prognosis ANewApproach toSimultaneouslyQuantify Both TCR aand b-Chain Diversity after Adoptive Immunotherapy (2012) (0)
IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy (2013) (0)
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 (2021) (0)
nsduction of Tumor-Specific T Cells with CXCR2 mokine Receptor Improves Migration to (2010) (0)
Abstract 3956: A novel compound screen for enhancing T-cell based immunotherapy identifies aurora kinases as a targetable mechanism for tumor immune escape in pancreatic ductal adenocarcinoma preclinical models (2019) (0)
Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. (2015) (0)
8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist (2020) (0)
ActivationImmunity through Localized TLR7/8 Effective Innate and Adaptive Antimelanoma (2014) (0)
Abstract 2549: Defective STAT1 activation associated with impaired IFN-γ production in lymphocytes from metastatic melanoma patients treated with HD IL-2 (2014) (0)
Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy (2020) (0)
Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort (2023) (0)
Cancer and the Cellular Immune Response (2014) (0)
Abstract 1836: Combining a novel retinoic acid receptor-γ agonist with immune checkpoint blockade represses lung cancer growth in vivo (2023) (0)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients (2019) (0)
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance (2015) (0)
and Antitumor Activity T Cell Numbers, Effector Function, + CD8 Enhances Peptide Vaccine-Induced a IFN-Helen (2009) (0)
Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts (2021) (0)
Abstract IA19: Rational combinations of targeted and immunotherapies (2016) (0)
ICOS signaling in CD8+ CTL contributes to the antitumor efficacy (P2122) (2013) (0)
18P Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting (2022) (0)
Genomic profiling and precision medicine in 3,745 patients with advanced cancer. (2014) (0)
A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM). (2018) (0)
Immuno-genomic landscape of osteosarcoma (2020) (0)
The role of transcription factor Runx2 in tumor infiltrating T cells (2013) (0)
Association of epithelial-mesenchymal transition with an immunosuppressive, inflammatory tumor microenvironment with elevated levels of checkpoint inhibitors in lung adenocarcinoma. (2015) (0)
Incidence and Severity of CMV Viremia After Desensitization With IVIG + Rituximab (RIT).: Abstract# A167 (2014) (0)
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy) (2021) (0)
229 CX3CR1 in exhausted CD8 T cell states (2021) (0)
Frequency of radiologically confirmed brain metastasis from time of diagnosis of stage IV disease in patients with melanoma. (2010) (0)
Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy (2019) (0)
Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity (2013) (0)
Abstract A13: Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma (2020) (0)
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. (2018) (0)
Abstract 5704: An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma (2023) (0)
A-toI RNA Editing Contrib utes to Proteomic Diversity in Cancer Graphical (2018) (0)
Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control (2015) (0)
Immune response changes in HPV-related vulvar malignancy (2019) (0)
Enhanced transgene expression improves immune responses following DNA vaccination (53.1) (2011) (0)
A comparison of the outcome of systemic therapy (Rx) of metastatic melanoma of unknown primary site (MUPS) and metastatic mucosal/cutaneous melanoma (MCM) (2005) (0)
Abstract CT127: Phase I adoptive cellular therapy trial with actively personalized, multi-targeted CD8+ T-cells in patients with relapsed and/or refractory solid cancers (ACTologIMA101-101) (2018) (0)
a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy (2020) (0)
Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. (2015) (0)
1279 A novel graphical deep neural network learning approach utilizing molecular data for optimizing patient selection for treatment with immune checkpoint inhibitors: An ORIEN pan-cancer study (2022) (0)
Abstract 4360: Inhibition of HSP90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes (2016) (0)
Abstract 3183: Adrenergic signaling augments cytotoxic T-cell anti-tumor function in p53-deficient head and neck cancer (2021) (0)
Abstract LB-096: Induction of systemic immunity through single-site intratumoral CD40 activation and checkpoint blockade eradicates melanoma in the brain (2016) (0)
Phase I study of nab-paclitaxel (NP) in combination with biochemotherapy (BCT) in patients (pts) with metastatic melanoma (MM). (2012) (0)
Successful tumor-infiltrating lymphocyte (TIL) growth from uveal melanoma (UM) using a three-signal (3.0) method. (2020) (0)
Immediate triggering of 4-1BB co-stimulation during initiation of tumor-infiltrating lymphocyte (TIL) expansion from melanoma tumors accelerates CD8+ T-cell outgrowth and tumor specificity (2013) (0)
Promising results from Phase III clinical trial of a peptide vaccine for advanced melanoma (2009) (0)
Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (0)
CANCER VACCINES TARGETING SURVIVIN IN PANCREATIC CANCER (2007) (0)
Table of Contents (1990) (0)
RNA editing derived epitopes function as cancer antigens to elicit immune responses (2018) (0)
Abstract 1017: Lipid metabolic reprogramming drives resistance to PD1 blockage (2017) (0)
Randomized S tudy o f H igh-Dose a nd L ow-Dose I nterleukin-2 in P atients W ith M etastatic R enal C ancer (2003) (0)
Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer (2015) (0)
Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM) (2018) (0)
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain (2017) (0)
Inducible Chemokines γ IFN-PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating (2012) (0)
Abstract D075: Investigating the immuno-biology underlying differential response to immunotherapy in White and non-White patients with metastatic acral melanoma (2020) (0)
Abstract A077: Sustained immune response to anti-PD-1 therapy for oral premalignant lesions (OPLs) in a carcinogen-induced oral cancer mouse model (2018) (0)
Activating the TNFR super family member 4-1BB pathway for the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy for metastatic melanoma patients. (P2119) (2013) (0)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) (2021) (0)
Management of venous thromboembolism (VTE) in melanoma patients with brain metastasis (2008) (0)
172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering (2021) (0)
IINovel Cytokine Endothelial-Monocyte Activating Polypeptide Is Determined by Tumor Production of the α Factor ( TNF )-Sensitivity of Human Melanoma to Tumor Necrosis In Vivo (2001) (0)
Immunotherapeutic strategies for melanoma: The role of anatomic site in vaccination and immune monitoring (2004) (0)
Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
Abstract 2372: Tumoral p53 mutations differentially mediate poor T-cell infiltration and autologous T-cell killing in preclinical models (2019) (0)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (0)
Abstract 5220: Increased expression of formyl peptide receptor (FPR) and formyl peptide receptor like-1 (FPRL1) correlates with high-risk clinical/histologic features in melanoma (2011) (0)
Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients (2015) (0)
Phase I/II study of weekly LOC-paclitaxel (LOC-pac) injection in patients (pts) with metastatic melanoma (MM). (2014) (0)
1085P Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors (2021) (0)
The role of the SWI/SNF complex in the tumor immune microenvironment (2020) (0)
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020 (2021) (0)
Targeted agents matched with tumor molecular aberrations: Review of 160 patients with advanced melanoma treated in a phase I clinic. (2012) (0)
Society for Melanoma Research 2013 Congress (2013) (0)
Predictive Biomarkers and Personalized Medicine Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy (2011) (0)
Ectoenzyme phenotype characterization of bone marrow derived macrophages (BMDM) (1984) (0)
Abstract 3279: All-trans-retinoic acid (ATRA) markedly augments anti-tumor immunity (2019) (0)
Abstract PR05: Control of the melanoma metastatic phenotype by A-to-I microRNA editing (2016) (0)
Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma. (2019) (0)
Abstract B022: Properties of T-cell-recognized neoantigens (2019) (0)
Clinical Cancer esearch cer Therapy : Preclinical nsduction of Tumor-Specific T Cells with CXCR 2 mokine Receptor Improves Migration to R or and Antitumor Immune Responses (2010) (0)
554 The panorama of tumor intrinsic immune regulators exhibited by genome-wide CRPISR immune screen integrated with comprehensive clinical dataset analysis (2021) (0)
1147 Differences in co-expression of T cell co-inhibitory and co-stimulatory molecules with PD1 across different human cancers (2022) (0)
Cancer Therapy : Clinical Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma (2012) (0)
Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099) (2022) (0)
Abstract 4002: Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398 (2016) (0)
Abstract PR03: Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype (2020) (0)
1462 Adrenergic signaling augments cytotoxic T cell anti tumor activity in p53 deficient cancers by CXCL10 release (2022) (0)
Natural history of metastatic melanoma patients with CNS metastases. (2006) (0)
Maturation Dysregulating Antigen-Presenting Cell T Cell Responses by + Inhibits CD 8 Colony-Stimulating Factor by Tumors Granulocyte-Macrophage Unopposed Production (1999) (0)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R af Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors (2019) (0)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes (2017) (0)
Abstract 3364: Epithelial-mesenchymal transition is associated with a profound inflammatory tumor microenvironment in lung adenocarcinoma (2015) (0)
CD8 T cells with high avidity TCR-ab specific for serine protease self-determinants for use in adoptive immunotherapy of human leukemia (2007) (0)
Abstract 2392: Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy (2016) (0)
Abstract 1575: The landscape of tumor intrinsic immune regulators revealed by genome-wide CRISPR immune screen integrated with comprehensive clinical data analysis (2021) (0)
Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment (2019) (0)
189 CRISPR-mediated metabolic reprograming of adoptively transferred T cells to potentiate antitumor response (2022) (0)
The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 (2022) (0)
The role of EGFR inhibitor (EGFRi) in immune cell infiltration and CD8+ T-cell activation in EGFR mutant lung cancer (2019) (0)
87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known (2021) (0)
Human Dendritic Cells Results in the Indoleamine 2 , 3-Dioxygenase Production by (2000) (0)
Phase II Study of Ipilimumab Plus Temozolomide in Patients with Metastatic Melanoma (2012) (0)
Abstract PL03-03: The rational combination of BRAF inhibition with immunotherapy for the treatment of metastatic melanoma (2012) (0)
Phase I/II study of LOC-paclitaxel (LOC-Pac) in patients (pts) with metastatic melanoma. (2012) (0)
Abstract 4010: Identification of novel targeted and immunotherapy combinations by a high throughput assay of T cell-mediated cytotoxicity (2016) (0)
782 Intratumoral sotigalimab with pembrolizumab activates antigen-presenting cells and induces local and distant anti-tumor responses in first-line metastatic melanoma: results of a phase I/II study (2022) (0)
1375 A hormone-based bispecific T cell engager (BiTE)-like molecule for the treatment of neuroendocrine tumors (2022) (0)
Advances in Brief Expression of a “ Self-” Antigen by Human Tumor Cells Enhances Tumor Antigen-specific CD 4 T-Cell Function (2002) (0)
Abstract 5703: The immune cell state atlas analysis predicts therapeutic benefits with immune checkpoint inhibitors (2023) (0)
An antibody drug conjugate targeting a GSTA glycosite-signature epitope of mucin1 expressed by non-small cell lung cancer (2019) (0)
Abstract 3655: Mast cells promote immunosuppression and pancreatic ductal adenocarcinoma development (2011) (0)
February 24, 2012 ऀð La Torreta Lake Resort Lake Conroe, TX Full Posters (2012) (0)
88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males (2021) (0)
624 Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses (2021) (0)
Abstract 1441: Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens (2016) (0)
Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy. (2019) (0)
An 11-gene expression signature related to tumorigenesis and immunosuppression in primary cutaneous melanoma predicts sentinel lymph node metastatic status. (2022) (0)
Increased Incidence of Renal Cell Carcinoma (RCC) Among Melanoma Patients (2012) (0)
Abstract 6425: Functional roles of enhancers in immune microenvironment & immunotherapy response (2023) (0)
Activated lymphocytes with dual specificity and their use methods (2002) (0)
Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin. (2014) (0)
Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (0)
CD8 T cells with high avidity TCR-ab specific for serine protease self-determinants for use in adoptive immunotherapy of human leukemia (48.35) (2007) (0)
Transduction and differentiation of dendritic cells from human hematopoietic progenitor cells (1996) (0)
Abstract 4385: PD-1 blockade enhances T-cell migration to tumor through induction of IFN-γ inducible chemokines (2012) (0)
The value of surveillance computed tomography scans of the pelvis in patients with head and neck primary melanomas. (2010) (0)
Abstract PR15: CD74 regulated inflammatory pattern is associated with TIL growth and favorable response to adoptive immunotherapy (2020) (0)
Abstract CT039: Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma (2022) (0)
B cells and tertiary lymphoid structures promote immunotherapy response (2020) (0)
T145: Comprehensive flow cytometry tracking of regulatory T cells and other lymphocyte subsets during HD IL-2 therapy for melanoma (2015) (0)
Metabolic plasticity of T-cell therapies: multi-omic profiling of interacting human tumor-infiltrating lymphocytes and autologous tumor adoptive cell therapy (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Patrick Hwu?

Patrick Hwu is affiliated with the following schools:

Utrecht University
University of Texas Health Science Center at Houston
Juntendo University
Massachusetts General Hospital
New York University
Thomas Jefferson University
Drexel University College of Medicine
University of Trieste
George Washington University
University of California, Berkeley
Emory University
University of Freiburg
MD Anderson Cancer Center
University of Sydney

Patrick Hwu's Academic­Influence.com Rankings

Why Is Patrick Hwu Influential?

Patrick Hwu's Published Works

Published Works

What Schools Are Affiliated With Patrick Hwu?

Patrick Hwu's AcademicInfluence.com Rankings